ProQR Therapeutics Short Interest Increases 50.9%

Summary

ProQR Therapeutics (NASDAQ: PRQR) saw a 50.9% increase in short interest in May, with a total of 567,400 shares shorted as of May 15th. This represents 0.8% of the company’s shares. The average trading volume was 588,100 shares, leading to a days-to-cover ratio of 1.0 days. The stock price dropped to $1.68, with a market cap of $176.76 million. Analysts’ ratings are mixed, with a consensus rating of ‘Moderate Buy’ and an average target price of $8.00 Market Beat. Additionally, Northern Trust Company significantly increased its holding in ProQR Therapeutics by 2550.1% in the fourth quarter, with other financial firms also acquiring shares Market Beat.

Impact Analysis

The increase in short interest by 50.9% indicates that a growing number of investors are betting against ProQR Therapeutics’ stock, which could put downward pressure on the stock price. This could be a response to perceived negative prospects for the company or broader market conditions affecting biotech stocks. The drop in stock price to $1.68 and a market cap of $176.76 million reflects this negative sentiment Market Beat. However, the significant increase in holdings by institutional investors such as Northern Trust Company and others suggests confidence in the company’s future prospects, which could counterbalance the negative sentiment from short sellers Market Beat. This mixed sentiment is reflected in the analyst consensus rating of ‘Moderate Buy.’ Investors should watch for any upcoming catalysts, such as product announcements or financial results, that could sway sentiment more positively or negatively.